Medicinova (MNOV) Research & Development (2010 - 2026)
Medicinova (MNOV) posted quarterly Research & Development of $1.5 million for Q4 2025, down 19.08% year-over-year from $1.9 million in Q4 2024, and down 2.5% quarter-over-quarter from $1.6 million in Q3 2025.
Medicinova (MNOV) Research & Development (2010 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Research & Development for 16 consecutive years, with $1.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 19.08% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $7.2 million (down 0.55% YoY), while the FY2025 annual figure was $7.2 million, down 0.55% from the prior year.
- Research & Development declined to $1.5 million in Q4 2025 per MNOV's latest filing, from $1.6 million in the prior quarter.
- Across five years, Research & Development topped out at $2.6 million in Q2 2022 and bottomed at $794706.0 in Q3 2023.
- Historically, Research & Development has averaged $1.9 million across 5 years, with a median of $1.8 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development slumped 67.62% — and 2024, when it surged 133.97%.
- Medicinova's Research & Development stood at $1.8 million in 2021, then increased by 13.26% to $2.0 million in 2022, then declined by 17.98% to $1.7 million in 2023, then grew by 15.55% to $1.9 million in 2024, then declined by 19.08% to $1.5 million in 2025.
- Business Quant data shows MNOV's Research & Development at $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Medicinova | 66.94 Mn | 66.94 Mn | 317,759.00 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 794,706.00 |
| Jun 30, 2023 | 1.74 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 2.01 Mn |
| Sep 30, 2022 | 2.45 Mn |
| Jun 30, 2022 | 2.56 Mn |
| Mar 31, 2022 | 2.11 Mn |
| Dec 31, 2021 | 1.78 Mn |
| Sep 30, 2021 | 2.09 Mn |
| Jun 30, 2021 | 2.53 Mn |